Yahoo · Sep 17, 2026
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
This company has succeeded where many others have failed.
RV
NASDAQ · RVMD
Revolution Medicines, Inc.
Healthcare · Biotechnology
$192.76
Up+$0.10 (+0.05%)
Updated Sep 22, 2026, 10:52 PM
SID Score
6.5/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 15.18B
- P/E ratio
- -15.46
- Dividend yield
- 0.00%
- 52-week range
- $42.18 – $224.31
- Volume
- 1.89M
- Avg. volume
- 2.27M
Price performance
RVMD price history
1M range · 0 trading sessions · Daily adjusted prices
RVMD does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest RVMD news
The latest Smart Investors Daily articles mentioning RVMD.
Stock researchCompany · Overview
RVMD research
Overview
Company profile and research snapshot.
Company profile
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $82.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | B of A Securities | Buy | — |
| Sep 10, 2026 | Morgan Stanley | Overweight | — |
| Sep 9, 2026 | Stifel | Buy | — |
| Aug 31, 2026 | Needham | Buy | — |
| Aug 28, 2026 | UBS | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 16, 2026
Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index’s 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services […]
Yahoo · Sep 16, 2026
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
New Preclinical PDAC Data for PRP Show >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Highlights How Reversing Epithelial-Mesenchymal Transition May Deepen & Extend Responses to RAS(ON) & Pan-RAS TherapiesMELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a co
SeekingAlpha · Sep 16, 2026
Baron Health Care Fund Q2 2026 Portfolio Activity
During the quarter, we added 8 new positions and exited 6 positions, bringing the number of positions in the Fund to 43.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
